In Tuesday’s Wall Street session, Gilead Sciences, Inc (NASDAQ:GILD) shares traded at $109.06, down -2.70% from the previous session.
GILD stock price is now 1.25% away from the 50-day moving average and 9.05% away from the 200-day moving average. The market capitalization of the company currently stands at $135.66B.
On March 04, 2025, Oppenheimer reiterated its ‘Outperform’ rating on the stock by increasing its target price from $115 to quote $132, while ‘Deutsche Bank’ rates the stock as ‘Buy’
In other news, JOHANNA MERCIER, Officer bought 3,000 shares of the company’s stock on Jul 15 ’25. The stock was bought for $333,090 at an average price of $111.03. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 15 ’25, Officer ANDREW DICKINSON bought 2,500 shares of the business’s stock. A total of $277,575 was incurred on buying the stock at an average price of $111.03. A total of 0.16% of the company’s stock is owned by insiders.
During the past 12 months, Gilead Sciences, Inc has had a low of $70.21 and a high of $119.96. As of last week, the company has a debt-to-equity ratio of 1.30, a current ratio of 1.37, and a quick ratio of 1.23. According to the stock market information, the enterprise value for the company is $154071416832, which is based on a 22.93 price-to-earnings ratio, a 0.88 price-to-earnings-growth ratio, and a beta of 0.35. The fifty day moving average price for GILD is $107.5926 and a two-hundred day moving average price translates $99.8783 for the stock.
The latest earnings results from Gilead Sciences, Inc (NASDAQ: GILD) was released for 2025-03-31. The net profit margin was 20.79% and return on equity was 32.51% for GILD. The company reported revenue of $6.67 billion for the quarter, compared to $6.69 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -0.28 percent.
